Preclinical data presented here support this combination of agents and show that tetratherapy increases the functionality of CD4+ and CD8+ T cells in the TME, which is associated with augmented anti-tumor efficacy relative to the triplet, doublet or singlets. Here, CD8A is linked to neoplasm.